Rationale, Dose Escalation for 67Cu-SAR-bisPSMA in Patients With mCRPC

Geoffrey Johnson, MD, PhD, of Mayo Clinic, provides context and an overview of the ongoing SECuRE study, a phase 1/2a theranostic trial for identification and treatment of PSMA-expressing mCRPC using targeted copper theranostics.

Dr. Johnson details the dose escalation process of the study, how anti-tumor efficacy is being evaluated, and more.